Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

• Status: Completed
• Trial end date: 2016-07-07
• Target enrollment: 0
• Participant gender: Female

Summary

This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. Dakin's solution may help reduce dermatitis caused by radiation therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Eusol; Pharmaceutical Solutions; Sodium Hypochlorite

Criteria

Inclusion Criteria:

• Women with breast cancer who plan to undergo radiation therapy to the breast or chest wall

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Women with scleroderma or discoid lupus

• Women with inflammatory breast cancer as evidenced by clinical assessment

• Women with breast cancer involving the skin

• Women who have undergone prior radiotherapy to the chest wall and/or breast